GlobeNewswire Inc.··Hutchmed (China) LimitedHUTCHMED Unveils Novel Cancer Therapy Data Ahead of AACR 2026 Meeting
HUTCHMED to present preclinical data on first-in-class PI3K/PIKK therapy and updated Phase Ib/II surufatinib combination trial results at AACR Annual Meeting 2026.
HCMoncologycancer therapy